Conversion from twice-daily to once-daily tacrolimus does not reduce intrapatient variability in tacrolimus exposure

Therapeutic Drug Monitoring

Volumn 37, Issue 2, 2015, Pages 262-269

  Shuker, Nauras ^a,b   Cadogan, Monique ^a   Van Gelder, Teun ^a,b   Roodnat, Joke I ^b   Kho, Marcia M L ^b   Weimar, Willem ^b   Hesselink, Dennis A ^b  

^a Clinical Pharmacology Unit ^*  (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

intrapatient variability; modified release; pharmacokinetics; tacrolimus

Indexed keywords

CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; AGED; ANCA ASSOCIATED GLOMERULONEPHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG INDUCED CANCER; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEADACHE; HEPATITIS C; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INSOMNIA; INTRAPATIENT VARIABILITY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; NON MELANOMA SKIN CANCER; ORAL CLEARANCE; OUTCOME ASSESSMENT; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RASH; URINARY TRACT INFECTION; ADOLESCENT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; GRAFT REJECTION; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; YOUNG ADULT;

EID: 84925934069     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000136     Document Type: Article

References (23)

1. Dew MA, DiMartini AF, De Vito Dabbs A, et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation. 2007;83:858-873.
2. Butler JA, Roderick P, Mullee M, et al. Frequency and impact of non-adherence to immunosuppressants after renal transplantation: a systematic review. Transplantation. 2004;77:769-776.
3. Kuypers DR, Peeters PC, Sennesael JJ, et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation. 2013;95: 333-340.
4. Kahan BD. High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection. Transplant Proc. 1998;30:1639-1641.
5. Borra LC, Roodnat JI, Kal JA, et al. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant. 2010;25:2757-2763.
6. Ro H, Min SI, Yang J, et al. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther Drug Monit. 2012;34:680-685.
7. Wehland M, Bauer S, Brakemeier S, et al. Differential impact of the CYP3A5∗1 and CYP3A5∗3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenet Genomics. 2011;21:179-184.
8. Alloway R, Steinberg S, Khalil K, et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc. 2005; 37:867-870.
9. Wu MJ, Cheng CY, Chen CH, et al. Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients. Transplantation. 2011;92:648-652.
10. Stifft F, Stolk LM, Undre N, et al. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. Transplantation. 2014;97:775-780.
11. van Hooff J, Van der Walt I, Kallmeyer J, et al. Pharmacokinetics in stable kidney transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations. Ther Drug Monit. 2012;34:46-52.
12. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol. 2005;34:215-220.
13. Davis CE. The effect of regression to the mean in epidemiologic and clinical studies. Am J Epidemiol. 1976;104:493-498.
14. Hesselink DA, Bouamar R, Elens L, et al. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2014;53:123-139.
15. Guirado L, Cantarell C, Franco A, et al. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. Am J Transplant. 2011;11:1965-1971.
16. Alloway R, Steinberg S, Khalil K, et al. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation. 2007; 83:1648-1651.
17. Kurnatowska I, Krawczyk J, Oleksik T, et al. Tacrolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus. Transplant Proc. 2011;43:2954-2956.
18. Kramer BK. Tacrolimus prolonged release in kidney transplantation. Expert Rev Clin Immunol. 2009;5:127-133.
19. Barraclough KA, Isbel NM, Johnson DW, et al. Once- versus twice-daily tacrolimus: are the formulations truly equivalent? Drugs. 2011;71:1561-1577.
20. Ho ET, Wong G, Craig JC, et al. Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. Transplantation. 2013;95:1120-1128.
21. Niioka T, Satoh S, Kagaya H, et al. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. Transplantation. 2012;94:1013-1019.
22. Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc. 2005; 37:1211-1213.
23. Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant. 2009; 9:2505-2513.